Colchicine for pericarditis

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Although the mechanism of benefi t is unclear, data support colchicine use in the management of recurrent pericarditis. Imazio et al. undertook a double blind trial of adults with acute pericarditis who were randomised to receive colchicine 0.5 mg twice daily (patient weight > 70 kg) or 0.5 mg daily (patient weight " 70 kg) for 3 months or placebo.
Original languageEnglish
Pages (from-to)325-325
Number of pages1
JournalJournal of Pharmacy Practice and Research
Volume43
Issue number4
DOIs
Publication statusPublished - 2013

Fingerprint

Pericarditis
Colchicine
Weights and Measures

Cite this

@article{987f16e8d15248be9b08714b7d5ce61d,
title = "Colchicine for pericarditis",
abstract = "Although the mechanism of benefi t is unclear, data support colchicine use in the management of recurrent pericarditis. Imazio et al. undertook a double blind trial of adults with acute pericarditis who were randomised to receive colchicine 0.5 mg twice daily (patient weight > 70 kg) or 0.5 mg daily (patient weight {"} 70 kg) for 3 months or placebo.",
keywords = "Management, recurrent pericarditis, acute pericarditis, randomised",
author = "Mark NAUNTON",
year = "2013",
doi = "10.1002/j.2055-2335.2013.tb00285.x",
language = "English",
volume = "43",
pages = "325--325",
journal = "Australian Journal of Hospital Pharmacy",
issn = "0310-6810",
publisher = "Wiley-Blackwell",
number = "4",

}

Colchicine for pericarditis. / NAUNTON, Mark.

In: Journal of Pharmacy Practice and Research, Vol. 43, No. 4, 2013, p. 325-325.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Colchicine for pericarditis

AU - NAUNTON, Mark

PY - 2013

Y1 - 2013

N2 - Although the mechanism of benefi t is unclear, data support colchicine use in the management of recurrent pericarditis. Imazio et al. undertook a double blind trial of adults with acute pericarditis who were randomised to receive colchicine 0.5 mg twice daily (patient weight > 70 kg) or 0.5 mg daily (patient weight " 70 kg) for 3 months or placebo.

AB - Although the mechanism of benefi t is unclear, data support colchicine use in the management of recurrent pericarditis. Imazio et al. undertook a double blind trial of adults with acute pericarditis who were randomised to receive colchicine 0.5 mg twice daily (patient weight > 70 kg) or 0.5 mg daily (patient weight " 70 kg) for 3 months or placebo.

KW - Management

KW - recurrent pericarditis

KW - acute pericarditis

KW - randomised

U2 - 10.1002/j.2055-2335.2013.tb00285.x

DO - 10.1002/j.2055-2335.2013.tb00285.x

M3 - Article

VL - 43

SP - 325

EP - 325

JO - Australian Journal of Hospital Pharmacy

JF - Australian Journal of Hospital Pharmacy

SN - 0310-6810

IS - 4

ER -